Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Principles of Pharmacogenetics: Types of Genetic Variants

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pharmacophore-Based Structure Optimization of <i>S</i>‑Trityl‑l‑Cysteine Derivatives for Cytotoxic Payload Applications.

ACS medicinal chemistry letters·2025

Same author

Identification of antimitotic sulfonamides inhibiting chromosome congression.

Biochemical pharmacology·2024

Same author

Crystal structure of the motor domain of centromere-associated protein E in complex with a non-hydrolysable ATP analogue.

FEBS letters·2023

Same author

Various effects of two types of kinesin-5 inhibitors on mitosis and cell proliferation.

Biochemical pharmacology·2021

Same author

Design, synthesis, and evaluation of a novel prodrug, a S-trityl-<sub>l</sub>-cysteine derivative targeting kinesin spindle protein.

European journal of medicinal chemistry·2021

Same author

2019 White Paper On Recent Issues in Bioanalysis: FDA BMV Guidance, ICH M10 BMV Guideline and Regulatory Inputs (<u>Part 2</u> - Recommendations on 2018 FDA BMV Guidance, 2019 ICH M10 BMV Draft Guideline and Regulatory Agencies' Input on Bioanalysis, Biomarkers and Immunogenicity).

Bioanalysis·2019

Search research articles

Related Experiment Video

Updated: Jun 22, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

[Pharmacogenomics].

Yoshiro Saito¹, Jun-ichi Sawada

¹Division of Functional Biochemistry and Genomics, National Institute of Health Sciences.

Nihon Rinsho. Japanese Journal of Clinical Medicine

|June 11, 2009

Summary

This summary is machine-generated.

Pharmacogenomics uses genetic biomarkers to predict drug response and safety. This review highlights recent advances in using genetic information for anti-cancer drugs, anti-platelet medications, and adverse reaction prediction.

Related Experiment Videos

Last Updated: Jun 22, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Area of Science:

Pharmacogenomics
Genetics
Drug Metabolism

Background:

Genetic variations influence individual drug responses, affecting pharmacokinetics and pharmacodynamics.
The field of pharmacogenomics is rapidly advancing, with established genetic biomarkers aiding drug safety and efficacy.
Personalized medicine relies on understanding genetic predispositions to drug effects.

Purpose of the Study:

To review recent advancements in pharmacogenomics.
To focus on specific genetic markers and their impact on drug response for key medications.
To highlight the clinical application of pharmacogenomics in predicting drug efficacy and adverse reactions.

Main Methods:

Literature review of recent pharmacogenomic studies.
Focus on specific drug-gene interactions: tegafur (CYP2A6), irinotecan (UGT1A1), cetuximab (KRAS mutations), clopidogrel (CYP2C19).
Inclusion of genetic markers for severe cutaneous adverse reactions (HLA-B) and myopathy (SLCO1B1).

Main Results:

Genetic polymorphisms significantly affect the efficacy and safety of drugs like tegafur, irinotecan, cetuximab, and clopidogrel.
Specific gene variants (e.g., CYP2A6, UGT1A1, KRAS, CYP2C19) are crucial for predicting patient response and risk.
Genetic markers such as HLA-B and SLCO1B1 are associated with severe adverse drug reactions and myopathy, respectively.

Conclusions:

Pharmacogenomic insights are essential for optimizing drug therapy and minimizing adverse events.
The clinical application of pharmacogenomics is expanding, enabling more precise and safer prescribing practices.
Continued research in pharmacogenomics will further personalize drug selection and dosage for improved patient outcomes.